Market cap
$27 Mln
Recently Viewed
Clear AllMarket cap
$27 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.5
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-70 Mln
ROE
-1.6 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-0.2
Debt to Equity
0.4
Book Value
$--
EPS
$-1.5
Face value
--
Shares outstanding
67,632,200
CFO
$-208.72 Mln
EBITDA
$-228.04 Mln
Net Profit
$-242.16 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Applied Genetic (AGTC)
| -79.3 | -1.6 | -4.2 | -82.5 | -48.4 | -36.5 | -- |
|
BSE Sensex*
| -7.3 | 5.3 | -4.1 | -1.1 | 9.6 | 10.5 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|---|---|---|---|---|---|---|---|
|
Applied Genetic (AGTC)
| -53.5 | -9.5 | 81.5 | -30.7 | -61.5 | -54.2 | -2.9 |
|
S&P Small-Cap 600
| 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 | -3.4 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Applied Genetic (AGTC)
|
0.4 | 26.6 | 0.3 | -70.2 | -21,080.9 | -217.2 | -- | 1.5 |
| 13.3 | 491.0 | 0.0 | -92.6 | -- | -47.5 | -- | 2.7 |
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology... development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida. Read more
Pres, CEO & Director
Ms. Susan B. Washer
Pres, CEO & Director
Ms. Susan B. Washer
Headquarters
Alachua, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Applied Genetic (AGTC) is $0.39 (NASDAQ) as of 09-Dec-2022 09:30 EDT. Applied Genetic (AGTC) has given a return of -48.43% in the last 3 years.
Since, TTM earnings of Applied Genetic (AGTC) is negative, P/E ratio is not available.
The P/B ratio of Applied Genetic (AGTC) is 1.51 times as on 09-Dec-2022, a 74 discount to its peers’ median range of 5.71 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.50
|
1.18
|
|
2021
|
-2.23
|
1.50
|
|
2020
|
-2.54
|
1.64
|
|
2019
|
-34.01
|
0.87
|
|
2018
|
-3.13
|
0.67
|
The 52-week high and low of Applied Genetic (AGTC) are Rs -- and Rs -- as of 23-Apr-2026.
Applied Genetic (AGTC) has a market capitalisation of $ 27 Mln as on 09-Dec-2022. As per SEBI classification, it is a Small Cap company.
Before investing in Applied Genetic (AGTC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.